Subjective cognitive impairment, mild cognitive impairment, and dementia
Conditions
Interventions
Donepezil:Donepezil
Memantine:Memantine
GV-971:Sodium oligomannate
Others:Other medicine
Sponsors
The First Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with subjective cognitive impairment, mild cognitive impairment or dementia; 2. Unlimited age; 3. Patients who are willing to participate in the clinical study and sign the informed consent of the study.
Exclusion criteria
Exclusion criteria: 1. Severe aphasia, physical disability or severe mental illness, violent tendencies and any other factors that may hinder the completion of the neuropsychological assessment; 2. Patients participating in clinical studies of other drugs; Pregnant or lactating women; 3. Men or women who are planning to become pregnant or undergo assisted reproductive technology.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MoCA (Montreal Cognitive Assessment) score /MMSE (Mini-mental State Examination) score decreased by 15% from baseline;All-cause death; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to first falling or fracture;Changing of NPI (Neuropsychiatric Inventory Questionnaire) score;Changing of MMSE score;Changing of ADCS-ADL (Alzheimer’s Disease Cooperative Study ADL Scale) score;Changing of MemTrax test;Number of patients CDR<=1;Changing of DSM-5 score;Changing of MoCA (Montreal Cognitive Assessment) score;Changing of MMSE (Mini-mental State Examination) score;Changing of ZBI (Zarit caregiver burden inventory) score; | — |
Countries
China
Contacts
Public ContactXiaolei Liu
The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China
Outcome results
None listed